First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck

被引：0
|
作者：
Even, C. [1 ]
Torossian, N. [2 ]
Ibrahim, T. [3 ]
Martin, N. [4 ]
Badis, L. Mayache [1 ]
Ferrand, F. R. [5 ]
Iacob, M. [1 ]
Guigay, J. [6 ]
Le Tourneau, C. [2 ]
Daste, A. [7 ]
Saada-Bouzid, E. [4 ]
Saleh, K. [1 ]
机构：
[1] Gustave Roussy Canc Ctr, Head & Neck Oncol Dept, Villejuif, France
[2] Inst Curie, Med Oncol, Paris, France
[3] Gustave Roussy, Med Oncol, Canc Campus, Villejuif, France
[4] Ctr Anticanc Antoine Lacassagne, Dept Med Oncol, Nice, France
[5] Begin Mil Teaching Hosp, Med Oncol, St Mande, France
[6] Ctr Anticanc Antoine Lacassagne, Med Oncol Direct, Nice, France
[7] CHU Bordeaux, Hop St Andre, Gironde, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1138P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
    Wurcel, Victoria
    Chirovsky, Diana
    Borse, Rebekah
    Altuna, Juan Ignacio
    Carabajal, Fernando
    Gandhi, Jyotika
    ADVANCES IN THERAPY, 2021, 38 (05) : 2613 - 2630
  • [22] REAL-WORLD USE OF PEMBROLIZUMAB COMBINATION REGIMENS IN FIRST-LINE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Black, Christopher
    Wang, Liya
    Ramakrishnan, Karthik
    Goto, Daisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A832 - A832
  • [23] Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study
    Liu, Yizhen
    Xue, Liqiong
    Xia, Zuguang
    Zhang, Qunling
    Guo, Ye
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (09): : 2040 - 2045
  • [24] Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
    Sun, Maxine
    Larcher, Alessandro
    Karakiewicz, Pierre I.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2014, 7 : 401 - 407
  • [25] PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Rischin, Danny
    Spigel, David R.
    Adkins, Douglas
    Wein, Richard
    Arnold, Susanne
    Singhal, Nimit
    Lee, Oliver
    Murugappan, Swami
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E1756 - E1761
  • [26] PembrolIzumab plus platinum and gemcitabine as first-line treatment of recurrent head and neck squamous cell carcinoma
    Ishak, W. Binti Wan
    Cheong, S.
    Nor, I. Muhamad
    Selvam, B.
    Ho, G.
    Tan, C.
    Wong, Y.
    Kue, P.
    Wai, A.
    Yahya, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1386 - S1386
  • [27] Oxaliplatin and capecitabine (XELOX) as first-line therapy for metastatic or relapsed squamous cell carcinoma of the head and neck
    Silva, O. E.
    Tolba, K.
    Farfan, N.
    Karr, M.
    Calfa, C.
    Raez, L. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
    Vienne, Agathe
    Collet, Laetitia
    Chevalier, Thomas
    Borel, Christian
    Tardy, Magalie
    Huguet, Florence
    Richard, Sandrine
    Salas, Sebastien
    Saada-Bouzid, Esma
    Fayette, Jerome
    Daste, Amaury
    BMC CANCER, 2023, 23 (01)
  • [29] Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
    Agathe Vienne
    Laetitia Collet
    Thomas Chevalier
    Christian Borel
    Magalie Tardy
    Florence Huguet
    Sandrine Richard
    Sebastien Salas
    Esma Saada-Bouzid
    Jerome Fayette
    Amaury Daste
    BMC Cancer, 23
  • [30] Efficacy and safety of pembrolizumab in recurrent or metastatic head and neck carcinoma as first-line therapy
    Ito, K.
    Nakanome, A.
    Morita, S.
    Imai, T.
    Asada, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1402 - S1402
12345